DE602006012995D1 - Brustkrebsdiagnoseverfahren - Google Patents

Brustkrebsdiagnoseverfahren

Info

Publication number
DE602006012995D1
DE602006012995D1 DE602006012995T DE602006012995T DE602006012995D1 DE 602006012995 D1 DE602006012995 D1 DE 602006012995D1 DE 602006012995 T DE602006012995 T DE 602006012995T DE 602006012995 T DE602006012995 T DE 602006012995T DE 602006012995 D1 DE602006012995 D1 DE 602006012995D1
Authority
DE
Germany
Prior art keywords
breast cancer
diagnostic procedure
cancer diagnostic
patient
target genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006012995T
Other languages
English (en)
Inventor
Alexander Krause
Philippe Leissner
Bruno Mougin
Malick Paye
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomerieux SA
Original Assignee
Biomerieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomerieux SA filed Critical Biomerieux SA
Publication of DE602006012995D1 publication Critical patent/DE602006012995D1/de
Anticipated expiration legal-status Critical
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE602006012995T 2005-07-07 2006-07-05 Brustkrebsdiagnoseverfahren Active DE602006012995D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0552087A FR2888252A1 (fr) 2005-07-07 2005-07-07 Procede pour le diagnostic du cancer du sein
PCT/FR2006/001593 WO2007006911A2 (fr) 2005-07-07 2006-07-05 Procede pour le diagnostic du cancer du sein

Publications (1)

Publication Number Publication Date
DE602006012995D1 true DE602006012995D1 (de) 2010-04-29

Family

ID=36295403

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006012995T Active DE602006012995D1 (de) 2005-07-07 2006-07-05 Brustkrebsdiagnoseverfahren

Country Status (7)

Country Link
US (1) US20090123924A1 (de)
EP (1) EP1917365B1 (de)
CN (1) CN101258250A (de)
AT (1) ATE461294T1 (de)
DE (1) DE602006012995D1 (de)
FR (1) FR2888252A1 (de)
WO (1) WO2007006911A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070280969A1 (en) * 2005-11-23 2007-12-06 The Johns Hopkins University RSF-1 as a prognostic marker and therapeutic target
WO2011039734A2 (en) * 2009-10-02 2011-04-07 Enzo Medico Use of genes involved in anchorage independence for the optimization of diagnosis and treatment of human cancer
WO2011060380A1 (en) * 2009-11-14 2011-05-19 The Regents Of The University Of California Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer
US9410188B2 (en) * 2010-05-28 2016-08-09 Biomerieux Method and kit for discriminating between breast cancer and benign breast disease
CN102680708B (zh) * 2012-05-14 2014-05-21 上海交通大学 诊断试剂盒及rnf19在制备胃癌早期诊断试剂中的应用
CN103602746A (zh) * 2013-11-26 2014-02-26 浙江省肿瘤医院 预测乳腺癌新辅助化疗疗效的生物标记物及其用途
CN103920150B (zh) * 2014-04-17 2016-02-03 北京大学第一医院 Satb1在治疗皮肤t细胞淋巴瘤中的应用
CN111172272A (zh) * 2020-01-17 2020-05-19 中国辐射防护研究院 Trip12基因用作辐射损伤易感性判断的分子标志物的用途
CN111154859A (zh) * 2020-01-17 2020-05-15 中国辐射防护研究院 一种trip12基因突变位点检测试剂盒及其用途
CN113930514A (zh) * 2021-11-22 2022-01-14 上海市东方医院（同济大学附属东方医院） 去泛素化酶usp25在制备诊断乳腺癌的生物标记物中的用途
CN114561411A (zh) * 2022-03-14 2022-05-31 贵州大学 Dicer1基因及其dsRNA在害虫防治中的应用
CN116355929A (zh) * 2023-04-11 2023-06-30 清华大学深圳国际研究生院 一种基于人ldhb基因启动子区的双荧光素酶报告基因载体及其构建方法和应用
CN116287277B (zh) * 2023-04-24 2024-08-06 上海生物制品研究所有限责任公司 胞苷脱氨酶活性的生物标记物及其应用
CN117959323B (zh) * 2024-01-12 2025-01-21 南方医科大学南方医院 环状rna在制备防治放射性肝纤维化的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
WO2002059271A2 (en) * 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
FR2833968A1 (fr) * 2001-12-20 2003-06-27 Ct Medico Chirurgical De Tronq Biopuces thematiques, comportant des modules de recherche associes ou couples, leur procede de preparation, et leurs applications
JP2008538007A (ja) * 2005-04-15 2008-10-02 ベクトン，ディッキンソン アンド カンパニー 敗血症の診断

Also Published As

Publication number Publication date
ATE461294T1 (de) 2010-04-15
WO2007006911A8 (fr) 2008-05-08
EP1917365A2 (de) 2008-05-07
CN101258250A (zh) 2008-09-03
WO2007006911A3 (fr) 2007-08-02
EP1917365B1 (de) 2010-03-17
WO2007006911A2 (fr) 2007-01-18
FR2888252A1 (fr) 2007-01-12
US20090123924A1 (en) 2009-05-14

Similar Documents

Publication Publication Date Title
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
DE602006012995D1 (de) Brustkrebsdiagnoseverfahren
PE20120015A1 (es) Metodos y sistemas para predecir la respuesta de las celulas tumorales a un agente terapeutico
IN2012DN00866A (de)
UA93989C2 (ru) Способ прогнозирования otbeta ha лечение
EP2185931A4 (de) Verwendung von secretor-, lewis- und sialyl-antigen-konzentrationen als krankheitsvorhersage-indikatoren
EP2569453A4 (de) Nukleinsäure-isolationsverfahren
CY1114719T1 (el) Ανταγωνιστικα ανθρωπινου light-ειδικα ανθρωπινα μονοκλωνικα αντισωματα
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
AR061136A1 (es) Procedimiento
NZ578283A (en) Proteomic profiling method useful for condition diagnosis and monitoring, composition screening, and therapeutic monitoring
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
ATE419516T1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
WO2010028373A3 (en) Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
EP2727935A3 (de) Mit Frühstadium und anderen Stadien von Brustkrebs assoziierte Serummarker
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
RU2014122607A (ru) Способы определения восприимчивости пациента к внутрибольничной инфекции и составления прогноза развития септического синдрома
BRPI0815460A2 (pt) kit de diagnóstico ou dispositivo e método para prognóstico de cancro em sujeitos mamíferos
EP1987165A4 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
WO2009019369A3 (fr) Procede de dosage de la plastine-i pour le diagnostic in vitro du cancer colorectal
FR2855832B1 (fr) Procede de diagnostic et/ou de pronostic d'un syndrome septique
EP2527358A3 (de) Diagnostischer Assay
DE602005016290D1 (de) Glichkeit
JP2013526869A5 (de)

Legal Events

Date Code Title Description
8364 No opposition during term of opposition